## <sup>112TH CONGRESS</sup> 1ST SESSION H.R. 741

To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.

## IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 16, 2011

Mrs. EMERSON introduced the following bill; which was referred to the Committee on Energy and Commerce

## A BILL

To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.

1 Be it enacted by the Senate and House of Representa-

2 tives of the United States of America in Congress assembled,

## **3** SECTION 1. PROHIBITION OF AUTHORIZED GENERICS.

4 Section 505 of the Federal Food, Drug, and Cosmetic
5 Act (21 U.S.C. 355) is amended by adding at the end the
6 following:

7 "(w) Prohibition of Authorized Generic 8 Drugs.—

9 "(1) IN GENERAL.—Notwithstanding any other
10 provision of this Act, no holder of a new drug appli-

| 1  | cation approved under subsection (c) shall manufac-    |
|----|--|
| 2  | ture, market, sell, or distribute an authorized ge-    |
| 3  | neric drug, direct or indirectly, or authorize any     |
| 4  | other person to manufacture, market, sell, or dis-     |
| 5  | tribute an authorized generic drug.                    |
| 6  | "(2) Authorized generic drug.—For pur-                 |
| 7  | poses of this subsection, the term 'authorized generic |
| 8  | drug'—   |
| 9  | "(A) means any version of a listed drug                |
| 10 | (as such term is used in subsection $(j)$ ) that the   |
| 11 | holder of the new drug application approved            |
| 12 | under subsection (c) for that listed drug seeks        |
| 13 | to commence marketing, selling, or distributing,       |
| 14 | directly or indirectly, after receipt of a notice      |
| 15 | sent pursuant to subsection $(j)(2)(B)$ with re-       |
| 16 | spect to that listed drug; and                         |
| 17 | "(B) does not include any drug to be mar-              |
| 18 | keted, sold, or distributed—                           |
| 19 | "(i) by an entity eligible for exclu-                  |
| 20 | sivity with respect to such drug under sub-            |
| 21 | section $(j)(5)(B)(iv)$ ; or                           |
| 22 | "(ii) after expiration or forfeiture of                |
| 23 | any exclusivity with respect to such drug              |
| 24 | under such subsection $(j)(5)(B)(iv)$ .".              |
|    |  |

 $\bigcirc$